Health ❯ Pharmaceuticals ❯ Drug Approval Process ❯ FDA Regulations

New Drug Application

Cytokinetics Faces Wave of Investor Lawsuits as Lead Plaintiff Deadline Nears

Plaintiffs allege Cytokinetics overstated its aficamten approval timeline by submitting an NDA without a REMS after FDA safety discussions.

Cytokinetics Investors Urged to Act as Lead‑Plaintiff Deadline Nears in REMS‑Related Securities Suit

Investor Firms Urge Cytokinetics Shareholders to Seek Lead Role in FDA-Disclosure Suit Before Nov. 17